A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma
Study Number: MK-6482-011
This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy.
The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantinib in terms of progression-free survival or overall survival.
Open in Peoria only
- Navigator Carrie, 309-243-3621 firstname.lastname@example.org
- Jessica, 309-243-3615, email@example.com
- Amanda , 309-243-3663, firstname.lastname@example.org